184 related articles for article (PubMed ID: 20215062)
21. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases.
Terpos E; Efstathiou E; Christoulas D; Roussou M; Katodritou E; Dimopoulos MA
Expert Opin Biol Ther; 2009 Apr; 9(4):465-79. PubMed ID: 19344283
[TBL] [Abstract][Full Text] [Related]
22. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.
Romas E; Sims NA; Hards DK; Lindsay M; Quinn JW; Ryan PF; Dunstan CR; Martin TJ; Gillespie MT
Am J Pathol; 2002 Oct; 161(4):1419-27. PubMed ID: 12368214
[TBL] [Abstract][Full Text] [Related]
23. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
24. Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats.
Roudier MP; Bain SD; Dougall WC
Clin Exp Metastasis; 2006; 23(3-4):167-75. PubMed ID: 16912914
[TBL] [Abstract][Full Text] [Related]
25. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.
Zhang J; Dai J; Yao Z; Lu Y; Dougall W; Keller ET
Cancer Res; 2003 Nov; 63(22):7883-90. PubMed ID: 14633717
[TBL] [Abstract][Full Text] [Related]
26. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.
Chanda D; Isayeva T; Kumar S; Siegal GP; Szafran AA; Zinn KR; Reddy VV; Ponnazhagan S
Mol Ther; 2008 May; 16(5):871-8. PubMed ID: 18388919
[TBL] [Abstract][Full Text] [Related]
27. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
28. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
29. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
Morony S; Capparelli C; Sarosi I; Lacey DL; Dunstan CR; Kostenuik PJ
Cancer Res; 2001 Jun; 61(11):4432-6. PubMed ID: 11389072
[TBL] [Abstract][Full Text] [Related]
30. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC; Chaisson M
Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
[TBL] [Abstract][Full Text] [Related]
31. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
32. Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.
Higgs JT; Jarboe JS; Lee JH; Chanda D; Lee CM; Deivanayagam C; Ponnazhagan S
Mol Cancer Res; 2015 May; 13(5):819-27. PubMed ID: 25636966
[TBL] [Abstract][Full Text] [Related]
33. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T; Feng X
Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
[TBL] [Abstract][Full Text] [Related]
34. The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma (Review).
Jimi E; Shin M; Furuta H; Tada Y; Kusukawa J
Int J Oncol; 2013 Mar; 42(3):803-9. PubMed ID: 23354319
[TBL] [Abstract][Full Text] [Related]
35. The role of osteoclastic activity in prostate cancer skeletal metastases.
Keller ET
Drugs Today (Barc); 2002 Feb; 38(2):91-102. PubMed ID: 12532187
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
37. [Clinical perspectives of the study of RANK/RANKL/OPG system components in primary and metastatic bone tumor].
Kushlinskiĭ NE; Timofeev IuS; Gershteĭn ES; Solov'ev IuN
Vopr Onkol; 2014; 60(4):413-21. PubMed ID: 25552059
[TBL] [Abstract][Full Text] [Related]
38. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.
Li X; Ominsky MS; Stolina M; Warmington KS; Geng Z; Niu QT; Asuncion FJ; Tan HL; Grisanti M; Dwyer D; Adamu S; Ke HZ; Simonet WS; Kostenuik PJ
Bone; 2009 Oct; 45(4):669-76. PubMed ID: 19539794
[TBL] [Abstract][Full Text] [Related]
39. In vitro blockade of receptor activator of nuclear factor-kappaB ligand prevents osteoclastogenesis induced by neuroblastoma cells.
Granchi D; Amato I; Battistelli L; Avnet S; Capaccioli S; Papucci L; Donnini M; Pellacani A; Brandi ML; Giunti A; Baldini N
Int J Cancer; 2004 Oct; 111(6):829-38. PubMed ID: 15300794
[TBL] [Abstract][Full Text] [Related]
40. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
